Stockscreener 앱 받기
51.72
1.90%
-1.00
시간 외 거래:
51.72
Alkermes Plc 주식(ALKS)의 최신 뉴스
Stifel raises Alkermes stock price target on orexin program outlook - Investing.com
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS) - simplywall.st
Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo
Press Release: Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo
Narcolepsy Treatments Are Advancing. Can Access? - Sleep Review
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study - Sahm
ALKS Maintained by Needham -- Price Target Raised to $62.00 - GuruFocus
TD Cowen raises Alkermes stock price target to $57 on drug data - Investing.com UK
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis - BioSpace
Alkermes releases nine-month data as OX2R race heats up - Clinical Trials Arena
Alkermes reports alixorexton narcolepsy trial data - grafa.com
What's Going on With Alkermes Stock Monday?Alkermes (NASDAQ:ALKS) - Benzinga
TD Cowen raises Alkermes stock price target to $57 on drug data By Investing.com - Investing.com South Africa
Alkermes (ALKS) Reports Positive Interim Results for Alixorexton in Narcolepsy Trials - GuruFocus
Alkermes reports nine-month narcolepsy drug trial results By Investing.com - Investing.com South Africa
JPMorgan Resumes Coverage of Alkermes (ALKS) with Neutral Rating - GuruFocus
ALKS Reinstated by JP Morgan -- Price Target Set at $60 - GuruFocus
Alkermes reports nine-month narcolepsy drug trial results - Investing.com
Experimental narcolepsy pill from Alkermes keeps patients awake and alert for up to nine months - Stock Titan
JPMorgan resumes Alkermes stock coverage with neutral rating By Investing.com - Investing.com Australia
JPMorgan resumes Alkermes stock coverage with neutral rating - Investing.com
Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF S - GuruFocus
Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF Score: 64/100 - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Alkermes plc Files 8-K Termination Report: Company Overview, NASDAQ Listing, and Key Details (July 2026) - Minichart
Enterprise value to EBITDA forward of Alkermes plc – NASDAQ:ALKS - TradingView
Alkermes plc outlines its role in neuroscience therapies as a global biopharmaceutical company - ad-hoc-news.de
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes stock hits 52-week high at 55.28 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 55.28 USD - Investing.com
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) notice: David Gaffin lists proposed Common Stock sales in 2026 - Stock Titan
Price to earnings forward of Alkermes plc – NASDAQ:ALKS - TradingView
Granules India secures sole First-to-File status for generic drug - The Times of India
ALKSAlkermes plc Volatility & Greeks - Finviz
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion - simplywall.st
ALKS Maintains Rating by Mizuho -- Price Target Raised to $65 - GuruFocus
Mizuho raises Alkermes stock price target to $65 on narcolepsy drug potential - Investing.com
Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance
A Look at Alkermes PLC (ALKS) After 4.8% Decline -- GF Value $31 - GuruFocus
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
0.56%
1.24%
자본화:
|
볼륨(24시간):